National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Dolutegravir/lamivudine (Dovato®), which is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

 

NCPE Assessment Process Complete
Rapid review commissioned 16/07/2019
Rapid review completed 26/08/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommend that dolutegravir /lamivudine (Dovato®) not be considered for reimbursement at the submitted price.*

 

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.